Your session is about to expire
← Back to Search
Combination Therapy for Langerhans Cell Histiocytosis
Study Summary
This trial is for kids with a rare cancer called Langerhans Cell Histiocytosis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 3 trial • 854 Patients • NCT00003389Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have lung failure, liver issues, or lung fibrosis due to LCH. I am not pregnant, breastfeeding, and I can sign consent.My diagnosis of Langerhans cell histiocytosis is confirmed by tissue examination.I have Langerhans Cell Histiocytosis with specific brain or bone involvement.My diagnosis of Langerhans cell histiocytosis is confirmed by tissue analysis.My non-risk organs are at least intermediate AD or my risk organs are better AD after 12 weeks.I have newly diagnosed single-system Langerhans Cell Histiocytosis not in my bones, brain, or 'CNS-risk' areas.My disease worsened after specific treatments and I have severe organ issues.I have LCH with specific brain MRI findings, regardless of my past treatments.I was under 18 when I was diagnosed.All patients from a specific program (LCH IV) who have not refused to be followed up for a long time.My LCH is worsening in critical organs but shows no active signs, and I or my guardian haven't consented in writing.My condition worsened in certain organs after treatment, and I now have severe organ dysfunction.I was diagnosed before turning 18.My cancer has worsened in certain areas after initial treatment.I have a specific liver condition without liver disease and poor kidney function.This is a specific group of people being targeted for the study.I am pregnant or have long-term effects from LCH without active disease, and have had prior systemic therapy.My condition has worsened in areas of my body not considered at high risk.This is a specific group within the study.
- Group 1: Stratum II
- Group 2: Stratum III
- Group 3: Stratum V
- Group 4: Stratum VI
- Group 5: Stratum IV
- Group 6: Stratum I
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what medical purposes is Vinblastine commonly prescribed?
"While most often given to small cell lung cancer patients, vinblastine has also been shown to ameliorate symptoms in those suffering from advanced testicular cancer, thyroiditis, and ulcerative colitis."
What is the sample size for this experiment?
"In order for this research to be conducted, 1400 individuals that fit the pre-determined criteria must agree to participate. Some of the locations where interested parties can sign up include Providence Sacred Heart Children's Hospital in Spokane, Washington and University of Kentucky A.B.Chandler Medical Center in Lexington, Kentucky."
Is this trial widespread throughout North America?
"Currently, this clinical trial is enrolling patients at 37 locations. While some of these sites are in Spokane, Lexington and New york, the other 34 sites are located elsewhere. By selecting the location closest to you, potential participants can minimize travel requirements."
Are researchers still enrolling people in this trial?
"Yes, this is an ongoing study that was initially posted on July 1st, 2014. The most recent update to the listing was on February 17th, 2022. Currently, 37 different medical facilities are recruiting 1400 patients in total."
Is Vinblastine a common medication in clinical trials?
"There are currently 780 active studies and 210 phase 3 clinical trials underway for the use of Vinblastine. Many of these research initiatives are based in Sacramento, California; however, there are 26774 locations worldwide where similar trials are being conducted."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger